Research
312 results
Name Type Target Compound Name Phase
InflaRx

Open-label, Randomized Study of IFX-1 in Patients With Severe COVID-19 Pneumonia (PANAMO)

New Therapies (Antibody-based) Complement 5a (C5a) IFX-1 Phase II / III
Korea University Guro Hospital

A Trial of Ciclesonide in Adults With Mild COVID-19

New Therapies (Small Molecule) Corticoid receptors Alvesco ciclesonide Phase II
DNAstack

Real-time Federated Search of Host and Viral Genomes. This project aims to develop technology to support fit-for-purpose real-time sharing, search, and analysis of viral and host genomes for COVID-19 and future disease outbreaks.

Research (AI) Covid-19 N/A Research
Imperial College London

Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial. (C-19-ACS)

New Therapies (Small Molecule) Cyclooxygenase-1 (COX-1) Aspirin In Clinic
Assistance Publique - Hôpitaux de Paris

Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection (ENACOVID)

New Therapies (Small Molecule) Cyclooxygenases (COX) Naproxen Phase III
OncoImmune

CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment (SAC-COVID)

New Therapies (Protein-based) DAMPs; SIGLEC10 CD24Fc Phase III
University of Miami

Effects of DPP4 Inhibition on COVID-19 Patients With Type 2 Diabetes

New Therapies (Small Molecule) Dipeptidyl peptidase-4 (DPP-4; CD26) Linagliptin Phase IV
Karyopharm

Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection (Coronavirus)

New Therapies (Small Molecule) Exportin 1 (XPO1; CRM1) Xpovio selinexor Phase II
Imperial College London

Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.

New Therapies (Small Molecule) Factor Xa Xarelto rivaroxaban In Clinic
NovaCell Technology

New Therapies (Small Molecule) Formyl peptide receptor 2 (FPR2) NCP112 Pre-Clinical
Collaboration: Partner Therapeutics & University Hospital Ghent in Belgium

Use of bone marrow stimulant sargramostim to treat COVID-19 patients

Research (Drug Repurposing) GM-CSF receptor Leukine sargramostim Phase IV
Humanigen

Use of Lenzilumab a clinical-stage, monoclonal antibody targeting GM-CSF,

New Therapies (Antibody-based) GM-CSF; CSF2 Lenzilumab Phase III
BioXyTran

The case for BXT-10 (by Bioxytran™) as a possible Galectin inhibitor for SARS-CoV-2 and therapeutic for COVID-19

New Therapies (Protein-based) Galectin-3; Galectin-1 BXT-10 Pre-Clinical
Doctor Negrin University Hospital

Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19 (DEXA-COVID19)

New Therapies (Small Molecule) Glucocorticoid receptor Dexamethasone Phase IV
University of Oxford

Low-cost dexamethasone reduces death by up to one third in hospitalized patients with severe respiratory complications of COVID-19.

New Therapies (Small Molecule) Glucocorticoid receptor dexamethasone Phase III
Pneumagen

Treat coronavirus COVID-19 infections using its first-in-class Carbohydrate Binding Modules (mCBMs)

New Therapies (Protein-based) Glycan receptors Neumifil Pre-Clinical
Imperial College London

Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.

New Therapies (Small Molecule) H+/K ATPase pump Omeprazole In Clinic
Collaboration: Ascletis Pharmaceuticals Co., Ltd. & The Ninth Hospital of Nanchang

Clinical trial of danoprevir/ritonavir combination therapy

Research (Drug Repurposing) HCV protease + HIV protease Ganovo danoprevir + ritonavir Phase IV
Collaboration: AbbVieGlobal hospital testing (AbbVie); World Health Organization SOLIDARITY trial (studying lopinavir/ritonavir with and without interferon beta); University of Oxford RECOVERY trial; REMAP-CAP global trial

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

Research (Drug Repurposing) HIV protease Kaletra lopinavir / ritonavir (Aluvia) Phase IV
Fiocruz

Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production

New Therapies (Small Molecule) HIV protease Atazanavir Pre-Clinical
Plan Nacional sobre el Sida (PNS)

Prevention of SARS-CoV-2 (COVID-19) Through Pre-Exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Hydroxychloroquine in Healthcare Personnel: Randomized Clinical Trial Controlled With Placebo

New Therapies (Small Molecule) HIV reverse transcriptase Emtricitabine/tenofovir disoproxil Phase III
Janssen Pharmaceutical Cos. (Johnson & Johnson)

Johnson & Johnson confirmed March 16 that it was screening its marketed HIV treatment Prezista and other antiviral compounds to determine potential in vitro effect against SARS-CoV-2

Research (Drug Repurposing) HIV-1 protease inhibitor; CYP3A inhibitor Prezista® (darunavir); Prezcobix™ (darunavir and cobicistat) Phase II / III
Imperial College London

Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.

New Therapies (Small Molecule) HMG-CoA reductase Atorvastatin In Clinic
Faron

investigational IV IFN beta-1a, hydrocortisone treatments, and other study treatment options on the clinical outcomes of COVID-19 patients and those with other causes of pneumonia requiring ICU care.

New Therapies (Protein-based) IFN receptor IV Interferon-β1a Pre-Clinical
EUSA Pharma

Trial of siltuximab, an anti-IL6 antibody for treatment of COVID-19

New Therapies (Antibody-based) IL-6 receptor (CD126) Sylvant siltuximab Phase II